BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Hepatitis
,
Neuron
,
Alcohol
,
Lovastatin
,
rs7903146
,
FXYD4
,
Angiogenesis
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
Tipifarnib
(compound)
Summary
General Info
Genetic Markers
Most Correlated Genes
No genes found
Explore Genetic Markers Results
Pathway Enrichment
Most Correlated Biogroups
No biogroups found
Explore Pathway Enrichment Results
Curated Studies
Most Correlated Studies
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (3 of 4)
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (2 of 4)
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (1 of 4)
Bone marrow from AML patients responsive or non-responsive to tipifarnib
Explore Curated Studies Results
Literature
Most Relevant Literature
Evolutionary dynamics of tipifarnib in HRAS mutated head and neck squamous cell carcinoma.
Small extracellular vesicles induce resistance to anti-GD2 immunotherapy unveiling tipifarnib as an …
Concomitant Acute Tubular Necrosis and Acute Interstitial Nephritis Induced by Tipifarnib in a Patie…
Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelo…
Tipifarnib Potentiates the Antitumor Effects of PI3Kα Inhibition in PIK3CA- and HRAS-Dysregulated HN…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Tipifarnib in Subjects With Myelodysplastic Syndromes
Tipifarnib in Advanced Squamous NSCLC With Oncogen HRAS MutAtionS
Tipifarnib in Treating Patients With Myelodysplastic Syndromes
Tipifarnib in Treating Patients With Advanced Hematologic Cancer
Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ